{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T19:01:59Z","timestamp":1784401319276,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P3-0343"],"award-info":[{"award-number":["P3-0343"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["J4-3606"],"award-info":[{"award-number":["J4-3606"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["L3-8213"],"award-info":[{"award-number":["L3-8213"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["L3-7538"],"award-info":[{"award-number":["L3-7538"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P3-0395"],"award-info":[{"award-number":["P3-0395"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ymgmr.2021.100836","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T01:23:59Z","timestamp":1639617839000},"page":"100836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Clinical and genetic characteristics of two patients with tyrosinemia type 1 in Slovenia \u2013 A novel fumarylacetoacetate hydrolase (FAH) intronic disease-causing variant"],"prefix":"10.1016","volume":"30","author":[{"given":"Jaka","family":"Sikonja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jernej","family":"Brecelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Zerjav Tansek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbka","family":"Repic Lampret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Drole Torkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Klemencic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neza","family":"Lipovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Stefanova Kralj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bertok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jernej","family":"Kovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Faganel Kotnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marketa","family":"Tesarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziga Iztok","family":"Remec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marusa","family":"Debeljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urh","family":"Groselj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ymgmr.2021.100836_bb0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s100240010146","article-title":"Tyrosinemia: a review","volume":"4","author":"Russo","year":"2001","journal-title":"Pediatr. Dev. Pathol."},{"key":"10.1016\/j.ymgmr.2021.100836_bb0010","first-page":"43","article-title":"Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type","volume":"19","author":"Angileri","year":"2015","journal-title":"JIMD Rep."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100836_bb0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s002470050551","article-title":"The kidney in children with tyrosinemia: sonographic,CT and biochemical findings","volume":"29","author":"Forget","year":"1999","journal-title":"Pediatr. Radiol."},{"issue":"7","key":"10.1016\/j.ymgmr.2021.100836_bb0020","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJM199002153220704","article-title":"Neurologic crises in hereditary tyrosinemia","volume":"322","author":"Mitchell","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ymgmr.2021.100836_bb0025","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.1840200513","article-title":"Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment","volume":"20","author":"van Spronsen","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.ymgmr.2021.100836_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/TACG.S113310","article-title":"Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)","volume":"10","author":"Das","year":"2017","journal-title":"Appl. Clin. Genet."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100836_bb0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10545-008-0793-1","article-title":"NTBC treatment in tyrosinaemia type I: long-term outcome in french patients","volume":"31","author":"Masurel-Paulet","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl 2","key":"10.1016\/j.ymgmr.2021.100836_bb0040","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1007\/PL00014321","article-title":"Indications and outcome of liver transplantation in tyrosinaemia type 1","volume":"158","author":"Mohan","year":"1999","journal-title":"Eur. J. Pediatr."},{"issue":"12","key":"10.1016\/j.ymgmr.2021.100836_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/gim.2017.101","article-title":"Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations","volume":"19","author":"Chinsky","year":"2017","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100836_bb0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13023-017-0599-z","article-title":"Newborn screening for tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy","volume":"12","author":"Stinton","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"7","key":"10.1016\/j.ymgmr.2021.100836_bb0055","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2213-8587(21)00092-9","article-title":"Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study","volume":"9","author":"Spiekerkoetter","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ymgmr.2021.100836_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1172-8-8","article-title":"Recommendations for the management of tyrosinaemia type 1","volume":"8","author":"de Laet","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"1\u20132","key":"10.1016\/j.ymgmr.2021.100836_bb0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cca.2010.09.027","article-title":"Monitoring tyrosinaemia type I: blood spot test for nitisinone (NTBC)","volume":"412","author":"Sander","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgmr.2021.100836_bb0070","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40272-019-00364-4","article-title":"Long-term outcomes and practical considerations in the pharmacological management of tyrosinemia type 1","volume":"21","author":"van Ginkel","year":"2019","journal-title":"Pediatr. Drugs"},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100836_bb0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/08880019809167228","article-title":"Alpha 1 -fetoprotein (AFP) reference values in infants up to 2 years of age","volume":"15","author":"Blohm","year":"1998","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ymgmr.2021.100836_bb0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cca.2019.05.007","article-title":"Comparison of liquid chromatography with tandem mass spectrometry and ion-exchange chromatography by post-column ninhydrin derivatization for amino acid monitoring","volume":"495","author":"Smon","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgmr.2021.100836_bb0085","series-title":"WPPSI-III: Technical and Interpretative Manual","author":"Wechsler","year":"2002"},{"key":"10.1016\/j.ymgmr.2021.100836_bb0090","series-title":"The Beery-Buktenica Developmental Test of Visual-motor Integration (Beery VMI) with Supplemental Developmental Tests of Visual Perception and Motor Coordination and Stepping Stones Age Norms: Administration, Scoring and Teaching Manual","author":"Beery","year":"2010"},{"key":"10.1016\/j.ymgmr.2021.100836_bb0095","series-title":"Adaptive Behavior Assessment System","author":"Harrison","year":"2015"},{"key":"10.1016\/j.ymgmr.2021.100836_bb0100","series-title":"Behavior Rating Inventory od Executive Function \u2013 Preschool Version","author":"Gioia","year":"2003"},{"key":"10.1016\/j.ymgmr.2021.100836_bb0105","series-title":"Manual for the ASEBA Preschool Forms & Profiles: An Integrated System of Multi-informant Assessment","author":"Achenbach","year":"2000"},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100836_bb0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13023-020-01547-w","article-title":"Type 1 tyrosinemia in Finland: a nationwide study","volume":"15","author":"\u00c4\u00e4rel\u00e4","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2021.100836_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13023-014-0107-7","article-title":"Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice","volume":"9","author":"Mayorandan","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"issue":"39","key":"10.1016\/j.ymgmr.2021.100836_bb0120","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017303","article-title":"Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain","volume":"98","author":"Couce","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100836_bb0125","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/(SICI)1098-1004(1996)7:3<239::AID-HUMU8>3.0.CO;2-5","article-title":"Fumarylacetoacetase mutations in tyrosinaemia type I","volume":"7","author":"Rootwelt","year":"1996","journal-title":"Hum. Mutat."},{"issue":"1\u20132","key":"10.1016\/j.ymgmr.2021.100836_bb0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2012.05.022","article-title":"Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Qu\u00e9bec","volume":"107","author":"Larochelle","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2021.100836_bb0135","first-page":"107","article-title":"Newborn screening for tyrosinemia type I: further evidence that succinylacetone determination on blood spot is essential","volume":"1","author":"la Marca","year":"2011","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2021.100836_bb0140","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/1756-0500-6-362","article-title":"Tyrosinemia type 1: a rare and forgotten cause of reversible hypertrophic cardiomyopathy in infancy","volume":"6","author":"Mohamed","year":"2013","journal-title":"BMC Res. Notes"},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100836_bb0145","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s10545-006-0203-5","article-title":"Cardiomyopathy in tyrosinaemia type I is common but usually benign","volume":"29","author":"Arora","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100836_bb0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13023-019-1280-5","article-title":"Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the european medicine agency for hereditary metabolic diseases in the MetabERN network","volume":"15","author":"Heard","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100836_bb0155","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4212\/cjhp.v68i3.1454","article-title":"Cost-consequence analysis of nitisinone for treatment of tyrosinemia type I","volume":"68","author":"Simoncelli","year":"2015","journal-title":"Can. J. Hosp. Pharm."},{"issue":"1","key":"10.1016\/j.ymgmr.2021.100836_bb0160","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13023-020-1343-7","article-title":"Dried blood spot versus venous blood sampling for phenylalanine and tyrosine","volume":"15","author":"van Vliet","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"1\u20132","key":"10.1016\/j.ymgmr.2021.100836_bb0165","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clinbiochem.2014.09.014","article-title":"Comparison of tandem mass spectrometry and amino acid analyzer for phenylalanine and tyrosine monitoring\u2013implications for clinical management of patients with hyperphenylalaninemia","volume":"48","author":"Groselj","year":"2015","journal-title":"Clin. Biochem."},{"issue":"7","key":"10.1016\/j.ymgmr.2021.100836_bb0170","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1023\/A:1005666426079","article-title":"Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia","volume":"23","author":"Wilson","year":"2000","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2021.100836_bb0175","first-page":"117","article-title":"Infants with tyrosinemia type 1: should phenylalanine be supplemented?","volume":"18","author":"van Vliet","year":"2015","journal-title":"JIMD Rep."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921001312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921001312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:54:53Z","timestamp":1778860493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426921001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":35,"alternative-id":["S2214426921001312"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100836","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and genetic characteristics of two patients with tyrosinemia type 1 in Slovenia \u2013 A novel fumarylacetoacetate hydrolase (FAH) intronic disease-causing variant","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100836"}}